Biomerica Inc Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Biomerica Inc has an operating margin of -96.7%, meaning the company retains $-97 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -117.6% the prior year.
Biomerica Inc's revenue declined 1.9% year-over-year, from $5.4M to $5.3M. This contraction results in a growth score of 23/100.
Biomerica Inc carries a low D/E ratio of 0.45, meaning only $0.45 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.80, Biomerica Inc holds $2.80 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 92/100.
Biomerica Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Biomerica Inc generates $0.77 in operating cash flow (-$3.8M OCF vs -$5.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Biomerica Inc (BMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Biomerica Inc generated $5.3M in revenue in fiscal year 2025. This represents a decrease of 1.9% from the prior year.
Biomerica Inc's EBITDA was -$5.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.7% from the prior year.
Biomerica Inc reported -$5.0M in net income in fiscal year 2025. This represents an increase of 16.8% from the prior year.
Biomerica Inc earned $-2.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.9% from the prior year.
Biomerica Inc held $2.4M in cash against $0 in long-term debt as of fiscal year 2025.
Biomerica Inc had 3M shares outstanding in fiscal year 2025. This represents an increase of 21.1% from the prior year.
Biomerica Inc's gross margin was 9.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the prior year.
Biomerica Inc's operating margin was -96.7% in fiscal year 2025, reflecting core business profitability. This is up 20.9 percentage points from the prior year.
Biomerica Inc's net profit margin was -93.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 16.8 percentage points from the prior year.
Biomerica Inc invested $1.0M in research and development in fiscal year 2025. This represents a decrease of 31.4% from the prior year.
BMRA Income Statement
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M-12.3% | $1.4M+23.3% | $1.1M-31.6% | $1.6M-9.5% | $1.8M+77.7% | $1.0M-35.1% | $1.6M-8.5% | $1.7M |
| Cost of Revenue | $1.2M+21.2% | $956K-13.1% | $1.1M-8.3% | $1.2M-21.0% | $1.5M+30.2% | $1.2M-6.1% | $1.2M-4.5% | $1.3M |
| Gross Profit | $51K-88.0% | $424K+2131.6% | $19K-95.7% | $437K+51.2% | $289K+294.0% | -$149K-145.8% | $325K-21.1% | $412K |
| R&D Expenses | $193K-9.0% | $212K-2.3% | $217K-15.6% | $257K-13.5% | $297K-13.4% | $343K-16.7% | $412K-12.7% | $472K |
| SG&A Expenses | $1.2M-7.4% | $1.3M+31.4% | $1.0M-13.7% | $1.2M-13.8% | $1.4M-9.8% | $1.5M-0.9% | $1.5M+29.8% | $1.2M |
| Operating Income | -$1.4M-22.8% | -$1.1M+7.6% | -$1.2M-21.9% | -$993K+27.4% | -$1.4M+31.6% | -$2.0M-24.4% | -$1.6M-30.5% | -$1.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $5K+66.7% | $3K+175.0% | -$4K-33.3% | -$3K-175.0% | $4K0.0% | $4K-50.0% | $8K-65.2% | $23K |
| Net Income | -$1.3M-66100.0% | $2K+100.2% | -$1.2M-22.4% | -$950K+27.8% | -$1.3M+31.4% | -$1.9M-27.3% | -$1.5M-33.1% | -$1.1M |
| EPS (Diluted) | $-0.45 | $0.00 | $-0.060.0% | $-0.06+90.5% | $-0.63-472.7% | $-0.11-22.2% | $-0.09-28.6% | $-0.07 |
BMRA Balance Sheet
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.0M-12.0% | $6.9M-7.1% | $7.4M+1.4% | $7.3M-7.6% | $7.9M-23.9% | $10.3M-12.6% | $11.8M-10.5% | $13.2M |
| Current Assets | $5.2M-12.0% | $5.9M-4.9% | $6.2M+4.4% | $5.9M-7.8% | $6.4M-27.1% | $8.8M-13.8% | $10.3M-11.3% | $11.6M |
| Cash & Equivalents | $2.5M-16.7% | $3.1M-0.2% | $3.1M+28.9% | $2.4M-15.9% | $2.8M-47.0% | $5.3M-25.4% | $7.1M-10.7% | $8.0M |
| Inventory | $1.5M+3.5% | $1.5M-11.0% | $1.7M-7.5% | $1.8M-7.9% | $1.9M-8.8% | $2.1M+15.6% | $1.8M-1.9% | $1.9M |
| Accounts Receivable | $947K-21.4% | $1.2M-5.0% | $1.3M-4.4% | $1.3M-14.5% | $1.6M+37.3% | $1.1M+5.9% | $1.1M-25.4% | $1.4M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.6M-5.9% | $1.7M-7.8% | $1.8M-14.7% | $2.2M-14.4% | $2.5M-0.4% | $2.5M+3.5% | $2.4M-0.1% | $2.5M |
| Current Liabilities | $1.6M-5.6% | $1.7M+2.7% | $1.6M-12.1% | $1.9M-12.8% | $2.2M+8.0% | $2.0M+9.3% | $1.8M+4.4% | $1.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.4M-14.0% | $5.2M-6.8% | $5.5M+8.2% | $5.1M-4.3% | $5.3M-31.5% | $7.8M-16.8% | $9.4M-12.9% | $10.8M |
| Retained Earnings | -$54.5M-2.5% | -$53.2M-3.0% | -$51.6M-2.3% | -$50.5M-1.9% | -$49.5M-5.9% | -$46.8M-4.3% | -$44.9M-3.5% | -$43.3M |
BMRA Cash Flow Statement
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$991K-269.8% | -$268K+74.4% | -$1.0M-32.1% | -$791K+41.1% | -$1.3M+25.4% | -$1.8M-113.9% | -$842K+49.7% | -$1.7M |
| Capital Expenditures | N/A | N/A | N/A | $24K | N/A | $0-100.0% | $6K-71.4% | $21K |
| Free Cash Flow | N/A | N/A | N/A | -$1.1M | N/A | -$1.8M-112.4% | -$848K+50.0% | -$1.7M |
| Investing Cash Flow | $0 | N/A | -$4K+83.3% | -$24K | N/A | -$16K-33.3% | -$12K+81.0% | -$63K |
| Financing Cash Flow | $482K-47.6% | $920K-47.0% | $1.7M | N/A | N/A | N/A | $7.3M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BMRA Financial Ratios
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 4.2%-26.5pp | 30.7%+29.0pp | 1.7%-25.0pp | 26.7%+10.7pp | 16.0%+30.6pp | -14.6%-35.4pp | 20.7%-3.3pp | 24.1% |
| Operating Margin | -113.5%-32.5pp | -81.0%+27.1pp | -108.1%-47.4pp | -60.7%+15.0pp | -75.7%+120.9pp | -196.7%-94.0pp | -102.6%-30.7pp | -71.9% |
| Net Margin | -109.1%-109.2pp | 0.1%+104.1pp | -103.9%-45.9pp | -58.1%+14.8pp | -72.8%+115.8pp | -188.6%-92.4pp | -96.2%-30.1pp | -66.1% |
| Return on Equity | N/A | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -21.9%-21.9pp | 0.0%+15.8pp | -15.8%-2.7pp | -13.1%+3.7pp | -16.7%+1.8pp | -18.6%-5.8pp | -12.7%-4.2pp | -8.6% |
| Current Ratio | 3.25-0.2 | 3.48-0.3 | 3.76+0.6 | 3.17+0.2 | 3.00-1.4 | 4.44-1.2 | 5.63-1.0 | 6.63 |
| Debt-to-Equity | 0.36+0.0 | 0.330.0 | 0.33-0.1 | 0.42-0.0 | 0.47+0.1 | 0.32+0.1 | 0.26+0.0 | 0.23 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -177.1%-123.0pp | -54.1%+44.8pp | -99.0% |
Similar Companies
Frequently Asked Questions
What is Biomerica Inc's annual revenue?
Biomerica Inc (BMRA) reported $5.3M in total revenue for fiscal year 2025. This represents a -1.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biomerica Inc's revenue growing?
Biomerica Inc (BMRA) revenue declined by 1.9% year-over-year, from $5.4M to $5.3M in fiscal year 2025.
Is Biomerica Inc profitable?
No, Biomerica Inc (BMRA) reported a net income of -$5.0M in fiscal year 2025, with a net profit margin of -93.6%.
What is Biomerica Inc's earnings per share (EPS)?
Biomerica Inc (BMRA) reported diluted earnings per share of $-2.16 for fiscal year 2025. This represents a 23.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Biomerica Inc's EBITDA?
Biomerica Inc (BMRA) had EBITDA of -$5.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biomerica Inc's gross margin?
Biomerica Inc (BMRA) had a gross margin of 9.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Biomerica Inc's operating margin?
Biomerica Inc (BMRA) had an operating margin of -96.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biomerica Inc's net profit margin?
Biomerica Inc (BMRA) had a net profit margin of -93.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biomerica Inc's operating cash flow?
Biomerica Inc (BMRA) generated -$3.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Biomerica Inc's total assets?
Biomerica Inc (BMRA) had $5.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Biomerica Inc spend on research and development?
Biomerica Inc (BMRA) invested $1.0M in research and development during fiscal year 2025.
How many shares does Biomerica Inc have outstanding?
Biomerica Inc (BMRA) had 3M shares outstanding as of fiscal year 2025.
What is Biomerica Inc's current ratio?
Biomerica Inc (BMRA) had a current ratio of 2.80 as of fiscal year 2025, which is generally considered healthy.
What is Biomerica Inc's debt-to-equity ratio?
Biomerica Inc (BMRA) had a debt-to-equity ratio of 0.45 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biomerica Inc's return on assets (ROA)?
Biomerica Inc (BMRA) had a return on assets of -83.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biomerica Inc's cash runway?
Based on fiscal year 2025 data, Biomerica Inc (BMRA) had $2.4M in cash against an annual operating cash burn of $3.8M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Biomerica Inc's Piotroski F-Score?
Biomerica Inc (BMRA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biomerica Inc's earnings high quality?
Biomerica Inc (BMRA) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Biomerica Inc?
Biomerica Inc (BMRA) scores 52 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.